Search 

Novartis is a large pharmaceutical company formed in 1996 and based in Basel, Switzerland. Novartis is an active investor in emerging life science companies via in-licensing, strategic partnerships, and acquisitions. Novartis also has a corporate VC fund (Novartis Venture Fund). 

Novartis has seven divisions, all of which accept collaboration proposals athttps://partnering.novartis.com: 

Novartis Pharmaceuticals is the largest division of Novartis; the division seeks innovative therapeutics that have attained proof of concept in humans, drug delivery technologies, process scale-up/development technologies, and drug manufacturing technologies. Novartis Pharmaceuticals also seeks molecular diagnostics in the oncology field and companion diagnostics that are connected with drug treatments. In addition to in-licensing, Novartis Pharmaceuticals is interested in joint regional commercialization for therapeutic products that are on the market. 

Novartis Institutes for Biomedical Research focuses on early-stage compounds and research technologies (including software, assay tools, disease models, screening and imaging tools, as well as therapeutic discoveries at the pre-proof of concept stage). 

Novartis Vaccines & Diagnostics seeks vaccines in late-stage clinical trials or on the market, vaccine development candidates, and vaccine-related technologies such as delivery, formulation, and adjuvants. 

Novartis Consumer OTC seeks OTC products and prescription products that could be switched to OTC status. Additionally Novartis OTC is interested in scientifically proven nutraceuticals and dietary supplements, innovative packaging technology, drug delivery devices or enabling technology platforms. The fund also invests in medical devices. Indications that Novartis OTC invests in include respiratory diseases, digestive health, pain, analgesics, diseases of the skin, and behavioral disorders (smoking-cessation). 

Novartis Animal Health seeks opportunities in the veterinary, agbio and aquaculture sectors. Indications of interest include musculoskeletal diseases (arthritis), renal diseases, heart disease and allergies in pets, and infectious and parasitic diseases in livestock. Subsectors of interest include animal vaccines and bioprotection (insecticides, fly control). Additionally Novartis Animal Health is interested in drug delivery in animals. 

Sandoz focuses on generics and is also interested in anti-infectives and injectable oncology drugs. 

Alcon focuses on treatments for diseases of the eye, and is interested in therapeutic products, surgical products and over-the-counter ophthalmic products such as contact lenses and lens care products.

Novelogics Biotechnology Inc. has developed unique next generation antibody immunotherapies for treating multiple types of advanced cancers including colon and prostate cancers.  Immunotherapies for cancer are anticipated to be a $35B per year industry in the upcoming years.  

Cancer Drugs with Safety in Mind

From the beginning the novel and specific design of the therapeutic antibody drug minimizes the potential for autoimmune diseases or harming good cells with the bad.  We are dedicated to making cancer treatments that won't make you sick to get you better.

Unecumbered, Founder Owned

Novelogics has developed their assets in an unecumbered envriornment allowing investors to work directly with the team.  At this time the companyis 100% founder owned and undiluted.  Novelogics is anticipating an early exit and has begun discussions with pharmaceutical companies interested in this area.

In addition; a related Medical Device

In addition to the drug, Novelogics has a second PCT Patent pending for a related medical device with a readily available "go to" market in place. 

NSF Health Sciences offers clinical, regulatory, and quality consulting services across the total product lifecycle for innovative medical device, pharmaceutical, and biotechnology companies.  We specialize in helping companies balance FDA and worldwide regulatory requirements with their business needs. 

NuvOx Pharma is developing a series of biologics that increase tissue oxygenation. The company's first market will be in oncology, where increased tumor oxygenation increases the response of tumors to radiation therapy. The company recently started a Phase 1b clinical trial in Glioblastoma Multiforme, and is raising a $2.5 million Series A to complete this trial. Afterwards it will seek partners for a Phase 2b in Glioblastoma, and Phase 1b trials in lung cancer and other oncology indications. After growing to a critical mass in oncology, the company will seek to become standard treatment to increase tissue oxygenation for patients suffering from heart attack, stroke, hemorrhaggic shock, and traumatic brain injury.

The NYU Office of Industrial Liaison (OIL) promotes the commercial development of NYU technologies into products to benefit the public, while providing resources to the University to support its research, education, and patient care missions. NYU OIL also facilitates research collaborations between NYU researchers and industry on projects of mutual interest.

In 2013, NYU launched the Office of Therapeutics Alliances (OTA). OTA is a nimble, "virtual biotech" approach to advance novel therapeutic projects by playing on the strengths of NYU in dissecting disease pathways and those of external, professional capabilities in early stage R&D. OTA identifies NYU projects with potential for addressing unmet needs, delineates the path to therapeutic proof of concept and assembles internal and external resources tailored to each specific project’s needs to maximize the likelihood of successful partnerships with biopharma, new biotech startups or disease foundations. 

O2h has a track record of investing in emerging biotech, small molecule and frontier life science starts-ups

A passion for entrepreneurship and life sciences motivates o2h to participate in syndicated seed stage investments. O2h are ready to support the investments with active or passive support to further the objectives of the company.

Comprising 10 investment professionals, Omnes Capital’s venture capital team acquires minority stakes in young companies with high growth potential. Its main areas of interest are financing innovative business ventures in the information technology and life sciences sectors (drug development, diagnostics, medical devices, bioproduction).

For 12 years, Omnes Capital has managed FCPI mutual funds (French regulated mutual funds investing in innovative companies).

ORIG3N is a biotech company based in Boston, MA. The scientific mission is to deliver a disease-modeling platform targeting rare genetically inherited diseases. By advancing screening projects using iPSC-derived differentiated cells and rapidly delivering the resulting data to inform therapeutic decisions, ORIG3N will replace trial & error guess work of treating disease and enable longer, healthier lives.